Treatment of Glioblastoma with Bevacizumab Has a New Standard Therapy been Defined?

被引：2
作者：
Chamberlain, Marc C. [1 ]
机构：
[1] Univ Washington, Fred Hutchison Canc Ctr, Seattle, WA 98109 USA
来源：
CNS DRUGS | 2011年 / 25卷 / 10期
关键词：
ENDOTHELIAL GROWTH-FACTOR; SINGLE-AGENT BEVACIZUMAB; ANGIOGENESIS; TEMOZOLOMIDE; IRINOTECAN; RADIATION; TRIAL;
D O I：
10.2165/11587880-000000000-00000
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：815 / 818
页数：4
相关论文
共 23 条
[1]  
Batchelor T, 2010, NEURO-ONCOLOGY, V12, P75
[2]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[3]   Emerging Clinical Principles on the Use of Bevacizumab for the Treatment of Malignant Gliomas [J].
Chamberlain, Marc C. .
CANCER, 2010, 116 (17) :3988-3999
[4]   Inhibition of angiogenesis and invasion in malignant gliomas [J].
Chi, Andrew ;
Norden, Andrew D. ;
Wen, Patrick Y. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (11) :1537-1560
[5]  
Chinot O, 2011, J CLIN ONCOL, V29, p16s
[6]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[7]   WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT [J].
FOLKMAN, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (01) :4-6
[8]   Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma [J].
Friedman, Henry S. ;
Prados, Michael D. ;
Wen, Patrick Y. ;
Mikkelsen, Tom ;
Schiff, David ;
Abrey, Lauren E. ;
Yung, W. K. Alfred ;
Paleologos, Nina ;
Nicholas, Martin K. ;
Jensen, Randy ;
Vredenburgh, James ;
Huang, Jane ;
Zheng, Maoxia ;
Cloughesy, Timothy .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4733-4740
[9]  
Genentech, FDA GRANTS ACC APPR
[10]  
GILBERT M, 2011, J CLIN ONCOL, V29, pS141
123